GSK plc
GSK plc (GSK) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for GSK plc (GSK), covering cash flow, earnings, and balance sheets.
GSK plc (GSK) Income Statement & Financial Overview
View the income breakdown for GSK plc GSK across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $7.52B | $8.12B | $8.01B | $7.88B |
| Cost of Revenue | $1.94B | $2.54B | $2.40B | $2.08B |
| Gross Profit | $5.58B | $5.58B | $5.62B | $5.80B |
| Gross Profit Ratio | $0.74 | $0.69 | $0.70 | $0.74 |
| R&D Expenses | $1.46B | $2.03B | $1.46B | $1.43B |
| SG&A Expenses | $2.07B | $2.66B | $3.80B | $2.39B |
| Operating Expenses | $3.36B | $4.88B | $5.43B | $3.82B |
| Total Costs & Expenses | $5.30B | $7.42B | $7.82B | $5.90B |
| Interest Income | $54.00M | -$22.00M | $32.00M | $24.00M |
| Interest Expense | $162.00M | $173.00M | $156.00M | $174.00M |
| Depreciation & Amortization | $823.00M | $412.00M | $951.00M | $639.00M |
| EBITDA | $3.09B | $1.12B | $1.17B | $2.85B |
| EBITDA Ratio | $0.41 | $0.14 | $0.15 | $0.36 |
| Operating Income | $2.22B | $696.00M | $189.00M | $1.99B |
| Operating Income Ratio | $0.29 | $0.09 | $0.02 | $0.25 |
| Other Income/Expenses (Net) | -$108.00M | -$133.00M | -$125.00M | -$151.00M |
| Income Before Tax | $2.11B | $563.00M | $64.00M | $1.50B |
| Income Before Tax Ratio | $0.28 | $0.07 | $0.008 | $0.19 |
| Income Tax Expense | $336.00M | $62.00M | -$1.00M | $191.00M |
| Net Income | $1.62B | $414.00M | -$58.00M | $1.17B |
| Net Income Ratio | $0.22 | $0.05 | -$0.007 | $0.15 |
| EPS | $0.40 | $0.10 | -$0.01 | $0.29 |
| Diluted EPS | $0.39 | $0.10 | -$0.01 | $0.28 |
| Weighted Avg Shares Outstanding | $4.09B | $4.08B | $4.08B | $4.08B |
| Weighted Avg Shares Outstanding (Diluted) | $4.14B | $4.14B | $4.14B | $4.12B |
Financial performance has remained strong, with revenue growing from $7.88B in Q2 2024 to $7.52B in Q1 2025. Gross profit continued to perform well, with margins at 74% in the latest quarter. Operating income reached $2.22B in Q1 2025, holding a steady 29% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $3.09B. Net income rose to $1.62B, keeping EPS at $0.40. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan